Adcitris 50mg Injection (Brentuximab Vedotin, Imported)
Overview
Adcitris is an advanced antibody-drug conjugate (ADC) designed for targeted cancer treatment. Each vial contains 50mg of Brentuximab Vedotin as a lyophilized powder, reconstituted and given through intravenous infusion over 30 minutes. It specifically targets CD30-positive cancer cells, delivering cancer-killing medicine directly into them while minimizing harm to healthy cells.
Indications
Adcitris is used for the treatment of:
-
Relapsed or refractory Hodgkin lymphoma, especially after stem cell transplant or failed chemotherapy.
-
Systemic anaplastic large cell lymphoma (sALCL) in patients not responding to standard therapy.
-
First-line treatment of advanced Hodgkin lymphoma (Stage III/IV), usually in combination with chemotherapy.
-
Certain CD30-positive T-cell lymphomas, such as primary cutaneous ALCL and peripheral T-cell lymphoma.
Dosage & Administration
-
Standard Dose (Monotherapy): 1.8mg/kg (up to 180mg maximum) once every 3 weeks.
-
Combination Therapy (Advanced Hodgkin Lymphoma): 1.2mg/kg (up to 120mg maximum) every 2 weeks.
-
Administered only under medical supervision as an intravenous infusion.
-
Dose adjustments may be required based on liver, kidney function, or patient tolerance.
Warnings & Precautions
-
Peripheral Neuropathy: Tingling, numbness, or weakness may occur with repeated doses.
-
Infusion Reactions: Some patients may develop allergic or severe reactions during infusion.
-
Hematologic Effects: Low white blood cells, anemia, or thrombocytopenia may occur; regular blood tests are required.
-
Infections: Increased risk of bacterial, viral, or fungal infections.
-
Liver & Lung Toxicity: Monitor for breathing difficulty or abnormal liver function tests.
-
Severe Skin Reactions: Rare but possible (Stevens-Johnson syndrome, TEN).
-
Pregnancy & Breastfeeding: Not recommended during pregnancy or while nursing.
Common Side Effects
-
Fatigue, fever, nausea, diarrhea, vomiting.
-
Skin rash or itching.
-
Cough, shortness of breath.
-
Decreased appetite, weight loss.
-
Neuropathy (numbness, tingling in hands/feet).
-
Low blood counts (neutropenia, anemia, thrombocytopenia).
Storage Instructions
-
Store vials in a refrigerator (2–8°C).
-
Protect from direct sunlight and moisture.
-
Reconstituted solution should be used immediately or within the timeframe recommended by the manufacturer.
Summary Table
Attribute | Details |
---|---|
Brand Name | Adcitris (Brentuximab Vedotin), Imported |
Strength | 50mg single-use vial |
Indication | Hodgkin lymphoma, sALCL, CD30+ T-cell lymphomas |
Dosage | 1.8mg/kg every 3 weeks (monotherapy); 1.2mg/kg every 2 weeks (combo) |
Route | Intravenous infusion (30 minutes) |
Side Effects | Neuropathy, fatigue, nausea, fever, infections, low blood counts |
Storage | Refrigerated, 2–8°C, protect from light and moisture |
✅ Meta Description (160 characters):